Medipharm Labs Corp. · TSX:LABS
Medipharm Labs — Investor Presentation (April 2020)
24 slides from Medipharm Labs's investor presentation, April 2020
Slide 1: MediPharm Labs: Global Leader in Pharma-Quality, Cannabinoid-Based Products
Hy t Ww MediPharm Labs Global Leader in Pharma-Quality, Cannabinoid-Based Products A Global Platfor A Global Market April 2020 medipharmlabs.com TSX:LABS..|_ OTCQX: MEDIF . | . FSE: MLZ
Slide 2: Disclaimer
Disclaimer April 2020– This presentation was prepared by management of MediPharm Labs Corp. (“MediPharm Labs”). The information contained in this presentation (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may b
Slide 3: A global leader in manufacturing pure, trusted and precisely doseable cannabis concentrates
A global leader in manufacturing pure, trusted and precisely doseable cannabis concentrates for advanced derivative products. Serving the global medical and wellness markets. www.medipharmlabs.com | 3
Slide 4: MediPharm Labs – A Global Growth Opportunity
MediPharm Labs – A Global Growth Opportunity (1) Adjusted EBITDA is not a recognized performance measure under IFRS, does not have a standardized meaning and therefore may not be comparable to similar measures presented by other issuers. A reconciliation of the Company’s operating income/(loss) to A
Slide 5: Key Milestones – Operational Highlights and Accomplishments
Key Milestones – Operational Highlights and Accomplishments www.medipharmlabs.com | 5
Slide 6: 2019 Operational Highlights & Accomplishments
2019 Operational Highlights & Accomplishments • First full year of profitability and a top five cannabis revenue company in the Canadian cannabis industry • Signed multiple new supplier agreements with other Cannabis Act licensed holders, direct-to-consumer brands, provincial and private retailers i
Slide 7: Fiscal 2019 Financial Summary
Fiscal 2019 Financial Summary(1) Revenue Gross Profit Adjusted EBITDA(1) (Loss) Net Income (Loss) Before • $129.3M in FY/19, a 1,168% increase • $42.9 M in FY/19, a 973% increase vs. • $24.7M in FY/19, a 2,844% increase vs. vs. $10.2M in 2018 $4M in 2018 ($0.9M) in 2018 Tax • Reflects scaling of sal
Slide 8: Flexible Business Model: Wholesale and White Label Platform
Flexible Business Model: Wholesale and White Label Platform www.medipharmlabs.com | 8
Slide 9: GMP Extraction Technology Platform to Drive Future Growth
GMP Extraction Technology Platform to Drive Future Growth Note: Launching of additional product lines remain subject to various risks and uncertainties, including the completion of applicable R&D, successful development of operations and regulatory approvals. See “Disclaimer – Cautionary Note Regard
Slide 10: Achieved GMP Certification to Access Emerging Global Markets
Achieved GMP Certification to Access Emerging Global Markets www.medipharmlabs.com | 10
Slide 11: Global Footprint – Expanding International Market Opportunities
Global Footprint – Expanding International Market Opportunities www.medipharmlabs.com | 11
Slide 12: Multiple Strategic Private and White Label Supply Agreements
Multiple Strategic Private and White Label Supply Agreements www.medipharmlabs.com | 12
Slide 13: New Product: MediPharm Labs CBD Regular Strength 25
NEW PRODUCT The first in a new medicinal & wellness product line, MediPharm Labs CBD REGULAR STRENGTH 25 is a pharma-quality CBD dominant oil containing 25 mg/mL of CBD using full spectrum cannabis concentrate produced to strict manufacturing standards. Available Soon at
Slide 14: Summary and Upcoming Catalysts
Summary and Upcoming Catalysts (1) All upcoming catalysts constitute forward-looking information and are subject to various risks and uncertainties. See “Disclaimer – Cautionary Note Regarding Forward-Looking Statements“. www.medipharmlabs.com | 14
Slide 15: Capital Structure and Ownership
Capital Structure and Ownership Stock Performance TSX:LABS – Up listed July 2019 (TSXV trading Oct 4, 2018) Capital Structure (as at December 31, 2019) $8.00 Volume (Millions) Price (C$ per Share) 8.0 Number Security (millions) $6.00 MediPharm Labs’ share price has 6.0 decreased by 20% Common Shares
Slide 16: Appendix
Appendix @medipharmlabs @medipharmlabs @medipharmlabs /medipharm-labs www.medipharmlabs.com | 16
Slide 17: Exceptional Management Team with Deep Experience
Exceptional Management Team with Deep Experience Pat McCutcheon Keith Strachan Bobby Kwon Chief Executive Officer President, Co-Founder Chief Financial Officer 15-year career in pharmaceutical sales and marketing A healthcare business development expert, 25-year career in international consumer-pack
Slide 18: Exceptional Management Team with Deep Experience
Exceptional Management Team with Deep Experience Dr. Chris Talpas Nigel Dewbury Michael Perron Vice President, Quality & Scientific Affairs Head of Quality Vice President, Business Development A Chromatography expert with 24-years in the Pharmaceutical & Medical Device industry A CPA with a MAcc, Mi
Slide 19: Exceptional Management Team with Deep Experience
Exceptional Management Team with Deep Experience Warren Everitt Dr. Jake Golding Adam Miller Chief Executive Officer, Asia Pacific Head of Quality, Australia Head of Strategic Accounts, Australia Warren brings senior leadership in Asia Pacific 20-years in bio-tech, with expertise in chemistry, 8-yea
Slide 20: Research and Development
Research and Development Health Canada Cannabis Research Licence Cannabis Research Licence under Health Canada’s Cannabis Act and Cannabis Regulations. This licence permits MediPharm Labs to conduct controlled human administration trials of dried cannabis, cannabis extracts and concentrates, distill
Slide 21: Science Advisory Committee (SAC)
Science Advisory Committee (SAC) The SAC will collaborate with the MediPharm Labs management team on advancements in the emerging fields of cannabinoid extraction and cannabinoid-based derivative science. This work will serve to further enhance the Company’s manufacturing platform and research pract
Slide 22: Quarterly Financial Summary
Quarterly Financial Summary Revenue Gross Profit Adjusted EBITDA (1) Net Income (Loss) Before • $32.4M in Q4/19, a 25% decrease vs. • $10M in Q4/19, a 32% decrease vs. • $2.7M in Q4/19, a 72% decrease vs. $43.4M in Q3/19 $14.8M in Q3/19 $10.1M in Q3/19 Tax • ($2.4M) in Q4/19, a 144% decrease vs • Re
Slide 23: 2019 Full Year Financial Summary
2019 Full Year Financial Summary Year Ended 3 Months Ended A ($000s) • Revenue $32.4M, a 25% decrease vs. $43.4M in Dec 31, 2019 Dec 31, 2019 Sept 30, 2019 June 30, 2019 Mar 31, 2019 Q3/19 Revenue $129,252 $32,444 $43,386 $31,472 $21,950 • Reflects reduction in average selling price A of bulk extrac
Slide 24: Please Contact for Additional Information
Please Contact for Additional Information Pat McCutcheon Chief Executive Officer @medipharmlabs Laura Lepore @medipharmlabs Vice President, Investor Relations and Communications @medipharmlabs Email: investors@medipharmlabs.com Phone: +1 416 913 7425 ext. 1525 /medipharm-labs